Open AccessEffectiveness and Safety of Favipiravir Compared to Hydroxychloroquine for Management of Covid-19: A Retrospective Study
Author(s) -
Musim Alotaibi,
Ahmed Ali,
Duaa Bakhshwin,
Yasser Alatawi,
Sultan Alotaibi,
Abdullah A. Alhifany,
Badr Alharthi,
Nasser Alharthi,
Awatef Alyazidi,
Yasmeen Alharthi,
Aziza Alrafiah
Publication year - 2021
Publication title -
international journal of general medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.722
H-Index - 36
ISSN - 1178-7074
DOI - 10.2147/ijgm.s329881
Subject(s) - medicine , hydroxychloroquine , retrospective cohort study , favipiravir , comorbidity , adverse effect , covid-19 , disease , infectious disease (medical specialty)
Coronavirus disease (COVID-19) is an infectious disease due to SARS-COV-2. Patients with risk factors are vulnerable to severe morbidity and mortality. Favipiravir (FPV) and hydroxychloroquine (HCQ) are considered possible COVID-19 treatments.